Hepatitis Monthly

Published by: Kowsar

Apolipoprotein C3 Gene Polymorphisms Are Not a Risk Factor for Developing Non-Alcoholic Fatty Liver Disease: A Meta-Analysis

Haiying Zhang 1 , 2 , 3 , Lizhen Chen 3 , Yongning Xin 4 , * , Yuangui Lou 1 , 2 , Yang Liu 3 and Shiying Xuan 4 , *
Authors Information
1 Department of Gastroenterology, The Second Affiliated Hospital of Qingdao University Medical College, Qingdao, China
2 Department of Gastroenterology, Qingdao Central Hospital, Qingdao, China
3 Medical College of Qingdao University, Qingdao, China
4 Department of Gastroenterology, Qingdao Municipal Hospital, Qingdao, China
Corresponding Authors:
Article information
  • Hepatitis Monthly: October 01, 2014, 14 (10); e23100
  • Published Online: October 15, 2014
  • Article Type: Review Article
  • Received: August 27, 2014
  • Revised: September 19, 2014
  • Accepted: September 23, 2014
  • DOI: 10.5812/hepatmon.23100

To Cite: Zhang H, Chen L, Xin Y, Lou Y, Liu Y, et al. Apolipoprotein C3 Gene Polymorphisms Are Not a Risk Factor for Developing Non-Alcoholic Fatty Liver Disease: A Meta-Analysis, Hepat Mon. 2014 ; 14(10):e23100. doi: 10.5812/hepatmon.23100.

Copyright © 2014, Kowsar Corp. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Context
2. Evidence Acquisition
3. Results
4. Discussion
  • 1. Duseja A, Aggarwal R. APOC3 and PNPLA3 in non-alcoholic fatty liver disease: need to clear the air. J Gastroenterol Hepatol. 2012; 27(5): 848-51[DOI][PubMed]
  • 2. Dam-Larsen S, Franzmann M, Andersen IB, Christoffersen P, Jensen LB, Sorensen TI, et al. Long term prognosis of fatty liver: risk of chronic liver disease and death. Gut. 2004; 53(5): 750-5[PubMed]
  • 3. Cortez-Pinto H, Baptista A, Camilo ME, De Moura MC. Nonalcoholic steatohepatitis--a long-term follow-up study: comparison with alcoholic hepatitis in ambulatory and hospitalized patients. Dig Dis Sci. 2003; 48(10): 1909-13[PubMed]
  • 4. Caldwell SH, Oelsner DH, Iezzoni JC, Hespenheide EE, Battle EH, Driscoll CJ. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology. 1999; 29(3): 664-9[DOI][PubMed]
  • 5. Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology. 2004; 40(6): 1387-95[DOI][PubMed]
  • 6. Chitturi S, Wong VW, Farrell G. Nonalcoholic fatty liver in Asia: Firmly entrenched and rapidly gaining ground. J Gastroenterol Hepatol. 2011; 26 Suppl 1: 163-72[DOI][PubMed]
  • 7. Duseja A, Sharma B, Kumar A, Kapil S, Das A, Dhiman RK, et al. Nonalcoholic fatty liver in a developing country is responsible for significant liver disease. Hepatology. 2010; 52(6): 2248-9[DOI][PubMed]
  • 8. Petersen KF, Dufour S, Hariri A, Nelson-Williams C, Foo JN, Zhang XM, et al. Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease. N Engl J Med. 2010; 362(12): 1082-9[DOI][PubMed]
  • 9. Miller M, Rhyne J, Chen H, Beach V, Ericson R, Luthra K, et al. APOC3 promoter polymorphisms C-482T and T-455C are associated with the metabolic syndrome. Arch Med Res. 2007; 38(4): 444-51[DOI][PubMed]
  • 10. Szczepaniak LS, Nurenberg P, Leonard D, Browning JD, Reingold JS, Grundy S, et al. Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am J Physiol Endocrinol Metab. 2005; 288(2)-8[DOI][PubMed]
  • 11. Conn VS, Rantz MJ. Research methods: managing primary study quality in meta-analyses. Res Nurs Health. 2003; 26(4): 322-33[DOI][PubMed]
  • 12. Huwiler-Muntener K, Juni P, Junker C, Egger M. Quality of reporting of randomized trials as a measure of methodologic quality. JAMA. 2002; 287(21): 2801-4[PubMed]
  • 13. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997; 315(7109): 629-34[PubMed]
  • 14. Valenti L, Nobili V, Al-Serri A, Rametta R, Leathart JB, Zappa MA, et al. The APOC3 T-455C and C-482T promoter region polymorphisms are not associated with the severity of liver damage independently of PNPLA3 I148M genotype in patients with nonalcoholic fatty liver. J Hepatol. 2011; 55(6): 1409-14[DOI][PubMed]
  • 15. Sentinelli F, Romeo S, Maglio C, Incani M, Burza MA, Scano F, et al. Lack of effect of apolipoprotein C3 polymorphisms on indices of liver steatosis, lipid profile and insulin resistance in obese Southern Europeans. Lipids Health Dis. 2011; 10: 93[DOI][PubMed]
  • 16. Hyysalo J, Stojkovic I, Kotronen A, Hakkarainen A, Sevastianova K, Makkonen J, et al. Genetic variation in PNPLA3 but not APOC3 influences liver fat in non-alcoholic fatty liver disease. J Gastroenterol Hepatol. 2012; 27(5): 951-6[DOI][PubMed]
  • 17. Peter A, Kantartzis K, Machicao F, Machann J, Wagner S, Templin S, et al. Visceral obesity modulates the impact of apolipoprotein C3 gene variants on liver fat content. Int J Obes (Lond). 2012; 36(6): 774-82[DOI][PubMed]
  • 18. Verrijken A, Beckers S, Francque S, Hilden H, Caron S, Zegers D, et al. A gene variant of PNPLA3, but not of APOC3, is associated with histological parameters of NAFLD in an obese population. Obesity (Silver Spring). 2013; 21(10): 2138-45[DOI][PubMed]
  • 19. Niu TH, Jiang M, Xin YN, Jiang XJ, Lin ZH, Xuan SY. Lack of association between apolipoprotein C3 gene polymorphisms and risk of nonalcoholic fatty liver disease in a Chinese Han population. World J Gastroenterol. 2014; 20(13): 3655-62[DOI][PubMed]
  • 20. Aalto-Setala K, Fisher EA, Chen X, Chajek-Shaul T, Hayek T, Zechner R, et al. Mechanism of hypertriglyceridemia in human apolipoprotein (apo) CIII transgenic mice. Diminished very low density lipoprotein fractional catabolic rate associated with increased apo CIII and reduced apo E on the particles. J Clin Invest. 1992; 90(5): 1889-900[DOI][PubMed]
  • 21. de Silva HV, Lauer SJ, Wang J, Simonet WS, Weisgraber KH, Mahley RW, et al. Overexpression of human apolipoprotein C-III in transgenic mice results in an accumulation of apolipoprotein B48 remnants that is corrected by excess apolipoprotein E. J Biol Chem. 1994; 269(3): 2324-35[PubMed]
  • 22. Zheng C, Khoo C, Ikewaki K, Sacks FM. Rapid turnover of apolipoprotein C-III-containing triglyceride-rich lipoproteins contributing to the formation of LDL subfractions. J Lipid Res. 2007; 48(5): 1190-203[DOI][PubMed]
  • 23. Li WW, Dammerman MM, Smith JD, Metzger S, Breslow JL, Leff T. Common genetic variation in the promoter of the human apo CIII gene abolishes regulation by insulin and may contribute to hypertriglyceridemia. J Clin Invest. 1995; 96(6): 2601-5[DOI][PubMed]
  • 24. Kozlitina J, Boerwinkle E, Cohen JC, Hobbs HH. Dissociation between APOC3 variants, hepatic triglyceride content and insulin resistance. Hepatology. 2011; 53(2): 467-74[DOI][PubMed]
  • 25. Diehl AM. Genetic susceptibility to hepatic steatosis. N Engl J Med. 2010; 362(12): 1142-3[DOI][PubMed]
  • 26. Sterne JA, Juni P, Schulz KF, Altman DG, Bartlett C, Egger M. Statistical methods for assessing the influence of study characteristics on treatment effects in 'meta-epidemiological' research. Stat Med. 2002; 21(11): 1513-24[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments